apricus wealth LLC Sells 8,703 Shares of Novartis AG (NYSE:NVS)

apricus wealth LLC lowered its position in shares of Novartis AG (NYSE:NVS) by 29.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 21,213 shares of the company’s stock after selling 8,703 shares during the period. Novartis accounts for approximately 1.6% of apricus wealth LLC’s investment portfolio, making the stock its 29th biggest holding. apricus wealth LLC’s holdings in Novartis were worth $2,440,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in NVS. Mcdaniel Terry & Co. grew its position in Novartis by 6.4% during the third quarter. Mcdaniel Terry & Co. now owns 6,190 shares of the company’s stock worth $712,000 after buying an additional 370 shares in the last quarter. Grey Fox Wealth Advisors LLC acquired a new stake in Novartis during the third quarter worth approximately $209,000. International Assets Investment Management LLC acquired a new stake in Novartis during the third quarter worth approximately $19,878,000. Monte Financial Group LLC grew its position in Novartis by 0.3% during the third quarter. Monte Financial Group LLC now owns 38,113 shares of the company’s stock worth $4,384,000 after buying an additional 114 shares in the last quarter. Finally, Greenleaf Trust grew its position in Novartis by 8.9% during the third quarter. Greenleaf Trust now owns 17,601 shares of the company’s stock worth $2,024,000 after buying an additional 1,445 shares in the last quarter. Institutional investors own 13.12% of the company’s stock.

Novartis Trading Down 0.8 %

NYSE NVS opened at $113.16 on Friday. The company has a quick ratio of 0.72, a current ratio of 0.93 and a debt-to-equity ratio of 0.47. Novartis AG has a twelve month low of $92.19 and a twelve month high of $120.92. The company has a market cap of $231.30 billion, a price-to-earnings ratio of 15.27, a price-to-earnings-growth ratio of 1.66 and a beta of 0.57. The business’s fifty day moving average is $116.44 and its 200 day moving average is $108.39.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on NVS. The Goldman Sachs Group reissued a “neutral” rating and set a $121.00 price target (up previously from $119.00) on shares of Novartis in a research report on Thursday, September 5th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Novartis in a report on Friday, July 19th. Jefferies Financial Group downgraded Novartis from a “buy” rating to a “hold” rating in a report on Tuesday, September 3rd. Finally, Bank of America downgraded Novartis from a “buy” rating to a “neutral” rating and reduced their target price for the company from $135.00 to $130.00 in a report on Wednesday, September 11th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Novartis currently has an average rating of “Hold” and a consensus target price of $120.70.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.